| 000 | 01918 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516103440.0 | ||
| 264 | 0 | _c20130220 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.27733 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMahadevan, Daruka | |
| 245 | 0 | 0 |
_aPhase 2 trial of combined cisplatin, etoposide, gemcitabine, and methylprednisolone (PEGS) in peripheral T-cell non-Hodgkin lymphoma: Southwest Oncology Group Study S0350. _h[electronic resource] |
| 260 |
_bCancer _cJan 2013 |
||
| 300 |
_a371-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aATP Binding Cassette Transporter, Subfamily B, Member 1 _xmetabolism |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCisplatin _xadministration & dosage |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 |
_aLymphoma, T-Cell, Peripheral _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMethylprednisolone _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 | _aGemcitabine |
| 700 | 1 | _aUnger, Joseph M | |
| 700 | 1 | _aSpier, Catherine M | |
| 700 | 1 | _aPersky, Daniel O | |
| 700 | 1 | _aYoung, Fay | |
| 700 | 1 | _aLeBlanc, Michael | |
| 700 | 1 | _aFisher, Richard I | |
| 700 | 1 | _aMiller, Thomas P | |
| 773 | 0 |
_tCancer _gvol. 119 _gno. 2 _gp. 371-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.27733 _zAvailable from publisher's website |
| 999 |
_c21975768 _d21975768 |
||